Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunogenicity: concepts/issues/concerns.

¹Division of Monoclonal Antibodies, CBER/FDA, Bethesda, MD, USA. kestein@erols.com

Developments in Biologicals

|November 19, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The regulation of biologic products derived from bioengineered plants.

Current opinion in biotechnology·2001

Same author

Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing.

Biotechnology progress·2001

Same author

The ability of B cells and dendritic cells to present antigen increases during ontogeny.

Journal of immunology (Baltimore, Md. : 1950)·2000

Same author

A novel activation induced lymphocyte surface antigen, 90.12, is also expressed on apoptotic cells.

Scandinavian journal of immunology·2000

Same author

Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine.

Infection and immunity·1999

Same author

Mutational analysis of avidity and fine specificity of anti-levan antibodies.

Journal of immunology (Baltimore, Md. : 1950)·1999

Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013

Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013

Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013

Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013

Same journal

Schmallenberg virus.

Developments in biologicals·2013

Same journal

Classical swine fever.

Developments in biologicals·2013

See all related articles

Therapeutic proteins, even if human-derived, can trigger immune responses in patients. Understanding the factors causing immunogenicity and antibody measurement is crucial for managing these responses.

Area of Science:

Biotechnology
Immunology
Pharmacology

Background:

Recombinant DNA technology enables the production of human proteins for therapeutic use.
Theoretically, these proteins should not elicit an immune response in humans.
However, clinical observations indicate that various forms of human proteins can be immunogenic.

Purpose of the Study:

To discuss the variables contributing to the immunogenicity of therapeutic proteins.
To review methods for measuring antibodies against therapeutic proteins.

Main Methods:

Literature review and discussion of existing data on protein immunogenicity.
Analysis of factors influencing immune responses to therapeutic proteins.

Main Results:

Related Experiment Videos

Fully human, partially human, and modified human proteins have demonstrated immunogenicity in patients.
Specific circumstances and patient factors influence the likelihood of an immune response.

Conclusions:

The immunogenicity of therapeutic proteins is a complex issue influenced by multiple factors.
Accurate measurement of anti-protein antibodies is essential for patient management and therapeutic efficacy.